4719 results about "Intestino-intestinal" patented technology

The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.

A method for the treatment and / or prophylaxis of an inflammatory condition of the intestine of a patient, comprises parenteral administration to the patient of an effective amount of high density lipoprotein (HDL).

The invention discloses preparation of a suckling piglet feed with low acid-binding capacity and a production method thereof. The feed is prepared from corn, bean pulp, fermented bean pulp, whey powder, vitamin, microelements and the like which serve as raw materials by special processing modes such as puffing, crushing, low-temperature granulation and the like. Through the feed and the preparation method, the defects of the conventional suckling piglet feed with high acid-binding capacity are overcome, the condition of low digestibility of the suckling piglet is reduced, the palatability of the feed is improved, the health of the intestinal canal of the piglet is improved and the productivity of the suckling piglets is improved.

The present invention provides new derivatives of 4- or 5-aminosalicylic acid, and a pharmaceutical composition containing these derivatives of 4- or 5-aminosalicylic acid as active ingredients, useful for the treatment of intestinal diseases such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) and for the prevention / treatment of colon cancer. More particularly, these derivatives comprise a hydrogen sulfide releasing moiety linked via an azo, an ester, an anhydride, a thioester or an amide linkage to a molecule of 4- or 5-aminosalicylic acid. Furthermore, the present invention provides a process for preparing these compounds and their use for treating IBD and IBS and the prevention / treatment of colon cancer.

The invention discloses a detection system and method for intestinal flora and a dynamic database. The detection system for the intestinal flora comprises: an acquisition device, an analysis and processing device, a storage device and a data processing device, wherein the acquisition device is used for acquiring information of the intestinal flora; the analysis and processing device is used for carrying out amplification processing on the acquired information of intestinal flora to obtain data of intestinal flora at every time of individual detection; the storage device is used for storing the data of intestinal flora; and the data processing device is used for comparing the data of intestinal flora of individuals at each time with the total quantity of the intestinal flora in the storage device. According to the detection system, an examinee can know self intestinal health condition composition through detection of the intestinal flora, and the examinee can know a difference value between oneself and healthy crowd, and then regulates aspects of diet, exercise, living habits and the like, thereby improving the condition of the intestinal flora and the body health condition. According to the dynamic database, the capacity of the database can be expanded in real time to obtain detection parameters of excrement of different types of people at the newest period.

The present invention relates to a nutritional additive comprising arabinoxylans, which beneficially modulates the human intestinal flora. Furthermore, several food and beverage products comprising the additive are provided as well as methods to prepare the said additive.

Compositions which deliver adsorbents, alone or in combination with active drug “degrading molecules,” in a site-specific manner to the intestine, and which eliminate or at least lower the concentration of residual unwanted material within the intestine, are disclosed. Methods of treatment using the compositions are also disclosed. The material to be eliminated can include residual active antibiotics, metabolites, bacterial or other toxins, and drugs which cause side effects in the gastrointestinal tract. The adsorbents can be formulated in capsules, tablets or any acceptable pharmaceutical composition, and are ideally designed to specifically release the adsorbents in a programmed manner at a specific site of the intestinal tract. The programmed delivery prevents adsorbents from interfering with the normal absorption process of a given molecule after oral absorption, until it reaches the lower part of the small intestine. The compositions can be used to adsorb, and therefore remove, any residual drug, metabolite thereof, or bacterial toxin after oral or parenteral administration which would otherwise cause adverse effects in the lower intestine and / or colon.

The invention belongs to the field of pharmacy and relates to a medicinal preparation taking esomeprazole magnesium as an active ingredient, in particular to an esomeprazole magnesium enteric-coated pellet and a preparation method thereof. According to the esomeprazole magnesium enteric-coated pellet, medicines can be rapidly released in intestinal tracts. The esomeprazole magnesium enteric-coated pellet comprises the following structural layers in sequence from inside to outside: a medicine-contained layer, an isolation layer and an enteric-coated layer.

The invention provides an Enterococcus faecium ANSE228 of which the collection number is CGMCC No.4082. The invention also provides application of the Enterococcus faecium ANSE228 to inhibition of salmonella pullorum and / or Escherichia coli and / or Staphylococcus aureus. The Enterococcus faecium ANSE228 is obtained by processes of repeated separation, purification, rejuvenation and the like, and has high biological activity, obvious probiotic property, high adversity resistance and the like. The invention also provides a microecological agent which contains the Enterococcus faecium ANSE228. When the microecological agent is added into drinking water and / or feeds for breeding animals, the Enterococcus faecium ANSE228 can be quickly activated and reproduced and a dominant beneficial flora can be formed after the Enterococcus faecium ANSE228 is fed into intestinal canals of the animals, and the Enterococcus faecium ANSE228 has the effects of reducing a harmful flora in the intestinal canals, adjusting microecological balance of the intestinal canals, substituting for medicaments such as antibiotic and the like, and improving weight increment of the animals and the utilization rate of the feeds.

The present invention comprises methods and compositions for the reduction of oxalate in humans, animals and plants. For example, the invention provides methods and compositions for the delivery of one or more oxalate-reducing pharmaceutical compositions to the intestinal tracts of persons and animals. The methods and compositions can be used in treating and preventing oxalate-related conditions. A composition of the invention comprises an oral delivery vehicle comprising an oxalate degrading bacteria, one or more cryopreserving agents and one or more excipients. A composition of the invention is enteric coated and has a suitable shelf-life and acceptable properties to avoid negative impact from gastric fluid when it is orally administered.

The invention relates to a high-activity probiotic composition suitable for infants and a preparation method thereof. The composition contains the following active components of: by weight, 0.33-3.3% of bifidobacteria, 45-60% of maltodextrin, 10-20% of glucose, 10-20% of whey powder and 5-10% of prebiotics. The preparation method comprises the following steps of: (1) drying the auxiliary materials until water activity (Aw) is less than or equal to 0.1; (2) replacing the air in a mixer with dry medical nitrogen; and (3) adding a few maltodextrin, adding probiotics, mixing for 5 minutes, adding residual maltodextrin and other raw and auxiliary materials, uniformly mixing, and discharging. The composition provided by the invention and functional foods (including health products) prepared by the composition have advantages of high safety of the probiotic strains and raw and auxiliary materials, balanced combination and appropriate bacteria number, are more suitable for Chinese infants' intestinal tracts, and have effects of enhancing infant's immunity and promoting the health of intestinal tract.